AVIATRIX
Aviatrix, the cloud network platform, today announced it has reached yet another significant milestone with its Aviatrix Certified Engineers (ACE) Program, while also launching a new multi-cloud network operations curriculum that builds on the basic cloud networking knowledge required to achieve ACE Multi-Cloud Networking Associate certification. The designation ACE Multi-Cloud Network Operations validates a cloud networking professional’s ability to successfully operate and manage multi-cloud networking and security services that support their organization’s needs. This course also introduces CI/CD and Infrastructure-as-a-Code (IaC) concepts, as more innovative solutions for operating cloud networking and security. Automation tools such as Terraform and the Aviatrix multi-cloud Terraform provider help operations an DevOps teams work closely together to deploy a repeatable and auditable infrastructure, leveraging a single CI/CCD pipeline.
With over 10,000 ACEs representing more than 2,500 companies, in over 110 countries worldwide, the Aviatrix ACE Program is the leading and most recognized multi-cloud networking technical certification. Specifically, this training program has helped cloud networking professionals and their companies close the skills gap, learn basic cloud service provider (CSP) constructs and how to add value by learning best practices for multi-cloud network architectures.
“Cloud networking is important but is also very complex. The Aviatrix ACE Program allows me to better understand the designs and limitations of all major cloud service providers (AWS, Azure, GCP, OCI, etc.,). This valuable education also helps architects and engineers design and build enterprise-class cloud networking solutions that meet enterprise-class security, performance, and compliance requirements. I strongly recommend this program to anyone interested in learning more about Hybrid or Multi-Cloud networking,” exclaimed Walter Lee, Sr. Software Engineer, at a leading global financial services company.
The ACE Program helps prepare an organization’s technical staff to lead and accelerate their transformation to cloud. The program is the first multi-cloud networking and security certification available to cloud practitioners, DevOps, networking staff, and security professionals. The ACE certification is designed for individuals who understand basic networking concepts and prepares engineers and operations staff with knowledge on (1) native cloud networking constructs in AWS, Azure, Google Cloud, and Oracle Cloud Infrastructure and (2) multi-cloud design patterns and concepts and (3) proficiency to plan and provision multi-cloud network use cases and architecture using the Aviatrix cloud network platform.
“The industry demand for the ACE Program over the past 12 months continues to exceed our expectations,” said Nauman Mustafa, Vice President Solutions Engineering, at Aviatrix. “With ACE, we provide the required training cloud networking professionals need to fully understand public-cloud networking constructs, service provider capabilities, different multi-cloud architectural design patterns, and how to apply this knowledge to their specific environment. Furthermore, our newly launched multi-cloud network operations course will enable the ACEs to successfully run, operate and efficiently manage their business-critical workloads in the cloud. They will also gain greater visibility, observability, and monitoring capabilities that go well beyond the basic operations and troubleshooting tools they get from their CSPs.”
Join the ACE Community Today!
To learn more about the ACE program, including the schedule for self-paced and instructor-led courses, course curriculum and other details, visit https://aviatrix.com/ace/ . Or email us at ace@aviatrix.com to request more information.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005239/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom